Impact of Thymosin α1 Duration on Survival in NSCLC Patients After R0 Resection: Clarifying Key Data
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. For patients who undergo R0 resection—complete surgical removal of the tumor—hope for a cure exists, but recurrence and long-term survival remain major concerns. Immunomodulatory therapies like thymosin α1 have emerged as promising adjuvants to boost post-surgical recovery by strengthening the immune system. But how does treatment duration affect outcomes? A 2021 study in the Chinese Medical Journal explored this question, and a recent corrigendum now clarifies critical data on how long patients should take thymosin α1 to maximize survival benefits.
The Original Study: What It Examined
Led by researchers including Guo CL, Mei JD, and colleagues from multiple institutions in China, the study used propensity score matching—a rigorous statistical method to balance patient characteristics (e.g., age, tumor stage, chemotherapy use)—to compare outcomes of NSCLC patients who received thymosin α1 after R0 resection versus those who did not. The team focused on two vital metrics:
- Disease-free survival (DFS): Time from surgery to cancer recurrence or death.
- Overall survival (OS): Time from surgery to death from any cause.
The Corrigendum: Correcting Key Survival Data
While the study’s core conclusions (that thymosin α1 improves survival and longer treatment is better) remain unchanged, the authors issued a corrigendum to fix hazard ratio (HR) values in Figure 3. HRs quantify how much treatment duration reduces (HR 1) survival risk. Below is the updated, accurate data on how thymosin α1 duration impacts DFS and OS:
What the Corrected Numbers Reveal
For disease-free survival (DFS) (Figure 3A):
- 12–24 months vs. <12 months: Patients who took thymosin α1 for 1–2 years had a 54% lower risk of recurrence or death than those on shorter courses (HR = 0.463; 95% confidence interval [CI]: 0.341–0.683; P = 0.0001).
- >24 months vs. <12 months: The biggest benefit came from treatment lasting over 2 years: a 72% lower risk of recurrence or death (HR = 0.284; 95% CI: 0.197–0.409; P < 0.0001).
- 12–24 months vs. >24 months: Even 1–2 years of treatment helped, but 2+ years was better. Patients on shorter long-term courses had a 63% higher risk of recurrence than those on extended treatment (HR = 1.632; 95% CI: 1.056–2.522; P = 0.0275).
For overall survival (OS) (Figure 3B):
- 12–24 months vs. <12 months: Taking thymosin α1 for 1–2 years cut the risk of death by 64% compared to shorter treatment (HR = 0.357; 95% CI: 0.216–0.588; P < 0.0001).
- >24 months vs. <12 months: The 2+ year group had an 83% lower risk of death (HR = 0.171; 95% CI: 0.107–0.272; P < 0.0001).
- 12–24 months vs. >24 months: Longer treatment won again—patients on 1–2 years of therapy had double the risk of death than those on extended courses (HR = 2.090; 95% CI: 1.175–3.717; P = 0.0121).
Why This Matters for Patients and Doctors
The corrigendum reinforces a clear message: longer thymosin α1 treatment after R0 resection is linked to better survival. Here’s what this means in practice:
- For patients: If your doctor recommends thymosin α1, adhering to longer treatment (especially >2 years) could significantly reduce your risk of recurrence or death.
- For clinicians: The updated data provides precise guidance on optimizing thymosin α1 use—longer courses offer the greatest benefit for eligible patients.
Importantly, the study’s propensity score matching ensures results are reliable: the team accounted for variables like age, tumor stage, and other treatments to isolate the effect of thymosin α1 duration on survival.
The Big Takeaway
Thymosin α1 works by activating immune cells (T-cells and natural killer cells) that target remaining cancer cells after surgery. The study’s results—strengthened by the corrigendum—suggest that the longer patients stay on this therapy, the more time their immune system has to eliminate residual cancer, leading to better long-term outcomes.
The original study was published in the Chinese Medical Journal (2021) by Guo CL, Mei JD, Jia YL, Gan FY, Tang YD, Liu CW, et al. The corrigendum clarifies Figure 3’s hazard ratio values to ensure accuracy.
doi.org/10.1097/CM9.0000000000001819
Was this helpful?
0 / 0